PsyOmics – follow-on investment
We are delighted to announce that the University of Cambridge Enterprise Fund V and the Parkwalk Opportunities Fund have invested in a follow-on financing round in PsyOmics, a spin-out from the Department of Chemical Engineering and Biotechnology. The… Read More
Horizon Discovery – Parkwalk UCEF I exit
We are delighted to have generated a 2.36x return (3.37x inclusive of initial tax reliefs) for our investors on the sale of the University of Cambridge Enterprise Fund I holding in Horizon Discovery plc. The investment was held for… Read More
Predictimmune – Parkwalk closes investment
We are delighted to announce that the Parkwalk Opportunities Fund and the University of Cambridge Enterprise Fund IV have completed an investment in Predictimmune Limited, a spinout company from the University of Cambridge.
Azul Optics – University of Bristol Enterprise Fund I investment
We are delighted to announce that the University of Bristol Enterprise Fund I, managed by Parkwalk, has invested in Azul Optics.
Parkwalk closes PhoreMost follow-on investment
We are pleased to announce that Parkwalk has made an investment in Phoremost, a Cambridge University spinout, as part of a Series ‘B’ round of equity funding, alongside Amadeus Capital Partners and the University. Phoremost’s mission is to accelerate,… Read More
Congenica – Parkwalk closes investment
We are delighted to announce that the Parkwalk Opportunities Fund and the Parkwalk Technology Fund VII have invested in a $10m Series ‘B’ financing round for Congenica Limited, which spun out of the Wellcome Trust Sanger Institute and Department… Read More
Sphere Fluidics – Parkwalk closes further funding round
We have closed a follow-on investment in Sphere Fluidics for the Opportunities Fund. This follows the UCEFs investing previously. Sphere Fluidics is an established Life Sciences company which has developed unique products for use in single cell analysis and characterisation and provides collaborative R&D… Read More
Polypharmakos – University of Cambridge Enterprise Fund IV investment
Cambridge and Kew join forces to find new antimicrobial substances in plants The Parkwalk-mamanged University of Cambridge Enterprise Fund IV and Cambridge Enterprise have invested £500k in Polypharmakos Limited, a spin-out from the University of Cambridge and the… Read More
Exonate – University of Bristol Enterprise Fund I investment
We are delighted to announce that the University of Bristol Enterprise Fund I, managed by Parkwalk, has invested in Exonate. Exonate are developing a novel approach to modulating new vessel growth. By controlling the balance of two contrasting forms of a… Read More
Horizon Discovery – Strong Revenue Growth and Focus on Operational Gearing Underpin Path to Profitability
Cambridge, UK, 20 September 2016: Horizon Discovery Group plc (LSE: HZD), a world leader in the application of gene editing technologies, announces its interim results for the six months ended 30 June 2016. Highlights (including post period end):… Read More
Micrima – University of Bristol Enterprise Fund I investment
We are delighted to announce that the University of Bristol Enterprise Fund I, managed by Parkwalk, has invested in Micrima. The company intends to develop and commercialise a new Breast Imaging System (MARIA) aimed at radically improving breast cancer… Read More
Fluidic Analytics – University of Cambridge Enterprise Fund IV and Parkwalk investment
Parkwalk have recently closed an investment in Fluidic Analytics for the University of Cambridge Enterprise Fund IV and Parkwalk Funds. Fluidic Analytics is developing a line of tools for the rapid, accurate, cost-effective analysis of proteins and other biomolecular species. By… Read More
PsyOmics – University of Cambridge Enterprise Fund IV investment
We are delighted to announce that the University of Cambridge Enterprise Fund IV, managed by Parkwalk, has invested in PsyOmics, a spin-out from the Department of Chemical Engineering and Biotechnology. The company aims to utilise blood-based diagnostics to… Read More
DefiniGEN – Parkwalk closes follow on investment
Parkwalk closes DefiniGen investment for the University of Cambridge Enterprise Fund IV and Parkwalk Funds DefiniGEN, a spin-out from the University of Cambridge Regenerative Medicine Department at Addenbrooke’s Hospital, have created a stem cell technology to provide human… Read More
Sphere Fluidics – University of Cambridge Enterprise Fund III closes further funding round
We have closed an investment, in a $7m funding round, in Sphere Fluidics for the University of Cambridge Enterprise Fund III. This follows the UCEFs I and II investing previously. The investment round has been led by an Asian corporate investor Sphere Fluidics… Read More
Oxford Endovascular – Parkwalk closes University of Oxford Isis Fund investment
We are delighted to announce that the University of Oxford Isis Fund II has completed an investment in Oxford Endovascular Limited, a company developing sophisticated mesh tubes to treat patients suffering from brain aneurysms. Parkwalk invested in a £2m round alongside the… Read More
Parkwalk closes Xerion investment
We are pleased to announce that the University of Oxford Isis Fund II has made an investment in Xerion, a nanoparticle company spun-out of the University with a novel treatment for cancer. Xerion seeks to commercialise Dr Helen Townley’s… Read More
Parkwalk closes Quethera investment
We are pleased to announce that the University of Cambridge Enterprise Fund III has made an investment in Quethera, a gene therapy company spun-out of the University with a novel treatment for glaucoma. Quethera announces seed financing to develop… Read More
Omega Diagnostics – Development Update
Omega Diagnostics Group PLC – Development Update – Visitect® CD4 and Allergy Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following development update on its infectious disease and allergy projects…. Read More
